{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1800","paramType":"Odds Ratio (OR)","paramValue":"0.85","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.2","upperLimit":"33.8","value":"30.5"},{"groupId":"OG001","lowerLimit":"24.6","upperLimit":"31.0","value":"27.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"762"}],"units":"Participants"}],"description":"Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"NUMBER","populationDescription":"All participants randomly assigned to study intervention. Participants with missing baseline ordinal scale values were excluded.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])","type":"PRIMARY","unitOfMeasure":"percentage of participants"}